Brief: Opthea Data For Opt-302 In Combination With Ranibizumab For Polypoidal Choroidal Vasculopathy (Pcv) Presented At Arvo 2022
May 5 (Reuters) - Opthea Ltd OPT.AX :
* OPTHEA DATA FOR OPT-302 IN COMBINATION WITH RANIBIZUMAB
FOR
POLYPOIDAL CHOROIDAL VASCULOPATHY (PCV) PRESENTED AT ARVO 2022
Source text for Eikon: ID:nGNX4cQ2jW
Further company coverage: OPT.AX
((reuters.briefs@thomsonreuters.com;))
Recent news on Opthea
See all newsBrief: Opthea To Recommence Trading On ASX On Or Around June 3, 2026
Brief: Opthea Says Hamish George Assumes Role Of CFO
Brief: Opthea Logs FY Prelim Loss Attributable $162.8 Mln
Australia's Opthea cuts 80% staff, key executives to exit in deal to avert bankruptcy (updated)
Brief: Opthea Says CEO Fred Guerard To Step Down